Plagued by low sales of its genetic tests, 23andMe adopts a bold new plan: slash prices and enter the pharmaceutical industry. But with investors nervous, can CEO Anne Wojcicki keep the show going long enough to make her DNA dream pay off?Be the first to know about Wondery’s newest podcasts, curated recommendations, and more! Sign up now at https://wondery.fm/wonderynewsletterListen to Business Wars on the Wondery App or wherever you get your podcasts. Experience all episodes ad-free and be the first to binge the newest season. Unlock exclusive early access by joining Wondery+ in the Wondery App or on Apple Podcasts. Start your free trial today by visiting wondery.com/links/business-wars/ now.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
Before the Crisis: How You and Your Relatives Can Prepare for Financial Caregiving
06 Dec 2025
Motley Fool Money
OpenAI's Code Red, Sacks vs New York Times, New Poverty Line?
06 Dec 2025
All-In with Chamath, Jason, Sacks & Friedberg
OpenAI's Code Red, Sacks vs New York Times, New Poverty Line?
06 Dec 2025
All-In with Chamath, Jason, Sacks & Friedberg
Anthropic Finds AI Answers with Interviewer
05 Dec 2025
The Daily AI Show
#2423 - John Cena
05 Dec 2025
The Joe Rogan Experience
Warehouse to wellness: Bob Mauch on modern pharmaceutical distribution
05 Dec 2025
McKinsey on Healthcare